GlycoTreat Announces Collaboration and Licence Option Agreement with a Global Veterinary Pharmaceutical Company

Amsterdam, The Netherlands - 21 May 2026.

GlycoTreat B.V. is pleased to announce the successful closing of a Collaboration and Licence Option Agreement with a global innovative pharmaceutical company active in the veterinary sector.

The parties will evaluate and advance GlycoTreat's proprietary immunomodulatory platform for veterinary applications, with an initial focus on allergic and inflammatory conditions in companion animals.

Under the agreement, the pharmaceutical partner has an option to obtain a licence to defined product candidates arising from the programme, subject to agreed terms and conditions. GlycoTreat will retain ownership of its pre-existing proprietary platform technology and contribute its scientific and technical expertise.

GlycoTreat's platform has potential applications across human and animal health. This agreement is focused on veterinary applications.

> "This agreement marks an important validation of GlycoTreat's technology and strategy in animal health," said Ina Margaretha Rijnhout, CEO of GlycoTreat. "Combining our innovation in immune modulation with the development, regulatory and commercial capabilities of a global veterinary pharmaceutical partner creates a strong foundation to bring new treatment options to animals suffering from allergic disease."

The agreement supports GlycoTreat's strategy to develop differentiated, science-based solutions for unmet needs in human and veterinary medicine. Financial terms, development milestones and the identity of the pharmaceutical partner are not being disclosed.

Contact:
Ina Margaretha Rijnhout, CEO | irijnhout@glycotreat.com |
www.glycotreat.com | https://www.linkedin.com/company/glycotreat/